Cardinol LA 160 mg is changing brand to Propranolol LA Lupin
The supplier has discontinued Cardinol LA 160 mg capsules. Pharmac has secured an alternative funded brand, Propranolol Lupin (S29)
Same medicine with the same active ingredient
Propranolol Lupin (S29) has the same active ingredient, with the same amount, as Cardinol LA. You should not notice any difference in how it works. Please see your doctor or pharmacist if you experience any issues. The packaging for Propranolol Lupin (S29) is labelled with both English and French text.
Propranolol Lupin (S29)
The new brand, Propranolol Lupin (S29) long-acting 160 mg capsules, will be listed (funded) from 1 August 2026.
Chemical: Propranolol hydrochloride
Brand: Propranolol Lupin (S29)
Pharmacode: 2734214
Subsidy: $35.15
Measure / Qty: per 100
When is this happening
You will notice your brand will change sometime after 1 August 2026.
Why is this happening?
The supplier, Viatris, has discontinued Cardinol LA 160 mg capsules (Pharmacode: 326070) in New Zealand and will stop supplying at the end of July 2026. To make sure people can continue to access this medicine, Pharmac has secured an alternative funded brand, Propranolol Lupin (S29) long-acting 160 mg capsules.
We know changing brands can be difficult and disruptive. We're sorry for any inconvenience this causes.
Medicine not Medsafe reviewed
This medicine has not been reviewed by Medsafe for use in New Zealand. However, it has been approved for use in other countries. Your prescriber will discuss this with you before they prescribe it. You can read more information about unapproved medicine on the Healthify website.
Unapproved medicines | Healthify.nz(external link)
Information for health care providers
From 1 August 2026 stat dispensing will be removed from propranolol LA cap 160 mg. Monthly dispensing will help to preserve stock until the supply chain is stable.
The alternate brand is not a Medsafe approved product and should be prescribed and supplied in line with Section 29A of the Medicines Act.
Subscribe to our health care professional updates to get weekly email updates about this and other supply issues.
Subscribe to our mailing list(external link)
Prescribing and supplying an unapproved medicine
Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people when there is supply issue affecting the registered brand.
We know supplying an unapproved medicine is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment.
We apologise for any inconvenience this causes.
What patients need to know about unapproved medicines – Healthify website(external link)
- Unapproved Medicine flier A5 [PDF 131 KB]
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
If you are a health care provider, please include as much information as you can about the product (presentation, brand, Pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)